DUBLIN,
May 16, 2017 /PRNewswire/ --
Allergan plc (NYSE: AGN) today announced the results of a new online eye language survey of 1,019 adult Americans that found approximately half of respondents (53 percent) say the eyes are the first facial feature they notice about another person. Research shows the eyes provide a powerful form of nonverbal communication about who we are and what we feel.
1 To help interpret our eye language,
Allergan has partnered with
Patti Wood, a body language expert with more than 25 years of experience.
The "A Look at Eye Language" online survey was conducted by Kelton Global on behalf of
Allergan in support of the brand's Eyepowerment campaign to raise awareness for Chronic Dry Eye disease.
"Eye language is a powerful form of communication that can reveal a lot about us, but Chronic Dry Eye symptoms like red or itchy eyes may unintentionally interfere with the message you want to send," said Wood. "My passion for interpreting our eye language aligns perfectly with
Allergan's Eyepowerment campaign, which aims to empower people who might be experiencing symptoms of Chronic Dry Eye to learn more about Chronic Dry Eye and talk to their doctor about treatment options."
Additional results of the survey revealed:
- Approximately 97 percent of America surveyed say that they are comfortable making eye contact with those that they know
- Those who see the value in maintaining eye contact say holding a direct gaze makes them feel respected (53 percent), understood (45 percent) or appreciated (44 percent)
- Many feel eye behavior creates a shared connection (36 percent), leaves a positive impression (35 percent) and increases one's likeability (29 percent)
- Women are more likely than men to feel eye behavior shows sincerity (53 percent vs. 41 percent) and creates a shared connection (42 percent vs. 30 percent)
- Approximately half of Americans (57 percent) can tell if someone is listening by looking into their eyes
- Approximately a quarter (28 percent) of respondents believe others know how truthful they are by looking into their eyes
Recognizing the importance of eye language and the messages our eyes can send,
Allergan's Eyepowerment campaign urges the up to 33 million Americans suffering from symptoms of Chronic Dry Eye to take action to learn about Chronic Dry Eye and talk to their doctor. Join the conversation by following @Eyepowerment on Twitter and using the hashtag #Eyepowerment.
Talk to your doctor or visit
Eyepowerment.com to learn more about the symptoms and treatment options for Chronic Dry Eye.
Survey Methodology:
"A Look at Eye Language" survey was conducted
between April 20 and April 25, 2017 among 1,019 nationally representative Americans ages 18 and over, using an e-mail invitation and an online survey. Quotas are set to ensure a reliable representation of the U.S. population 18 and over. In this survey, Millennials were defined as those ages 18-36.
Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results.
In this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 3.1 percent, from the result that would be obtained if interviews had been conducted with all personas in the universe represented by the sample. The margin of error for any subgroups will be slightly higher.
About Kelton
Kelton Global is a leading global insights firm serving as a partner to more than 100 of the Fortune 500 and thousands of smaller companies and organizations. For more information about Kelton Global please call 1.888.8.KELTON or visit
http://keltonglobal.com.
About Dry Eye
One type of chronic dry eye is caused by reduced tear production due to inflammation. Dry eye is often a chronic disease that can be caused by advanced age, contact lens wear, certain medications, eye diseases, other medical conditions or environmental factors. Without enough tears, the film protecting the eye can break down, creating dry spots on the cornea.
About Allergan plc Allergan plc (NYSE: AGN), headquartered in
Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach,
Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs currently in development.
Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit
Allergan's website at
www.Allergan.com.
Forward-Looking Statement Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect
Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from
Allergan's current expectations depending upon a number of factors affecting
Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of
FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for
Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the
Securities and Exchange Commission, including but not limited to
Allergan's Annual Report on Form 10-K for the year ended
December 31, 2016 and
Allergan's Quarterly Report on Form 10-Q for the period ended
March 31, 2017. Except as expressly required by law,
Allergan disclaims any intent or obligation to update these forward-looking statements.
References: 1 Lee DH,
Anderson AK. "Reading what the mind thinks from how the eye sees ",
Psychol. Sci. 2017; 28(4): 494-503.
